PortfoliosLab logoPortfoliosLab logo
AxoGen, Inc. (AXGN)
Performance
Return for Risk
Dividends
Drawdowns
Volatility
Financials

Company Info

ISIN
US05463X1063
CUSIP
05463X106
IPO Date
Mar 27, 1990

Highlights

Market Cap
$1.55B
Enterprise Value
$1.54B
EPS (TTM)
-$0.34
Total Revenue (TTM)
$225.21M
Gross Profit (TTM)
$167.35M
EBITDA (TTM)
$7.55M
Year Range
$9.22 - $36.00
Target Price
$38.38
ROA (TTM)
-7.08%
ROE (TTM)
-12.19%

Share Price Chart


Loading graphics...

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


AxoGen, Inc.

Often compared with AXGN:
AXGN vs. SPY

Performance

Performance Chart

The chart shows the growth of an initial investment of $10,000 in AxoGen, Inc., comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends.


Loading graphics...

S&P 500 Index

Returns By Period

AxoGen, Inc. (AXGN) has returned 1.22% so far this year and 79.08% over the past 12 months. Looking at the last ten years, AXGN has achieved an annualized return of 19.91%, outperforming the S&P 500 Index benchmark, which averaged 12.16% per year.


AxoGen, Inc.

1D
5.78%
1M
4.41%
YTD
1.22%
6M
85.71%
1Y
79.08%
3Y*
51.91%
5Y*
10.78%
10Y*
19.91%

Benchmark (S&P 500 Index)

1D
2.91%
1M
-5.09%
YTD
-4.63%
6M
-2.39%
1Y
16.33%
3Y*
16.69%
5Y*
10.18%
10Y*
12.16%
*Multi-year figures are annualized to reflect compound growth (CAGR)

Monthly Returns

Based on dividend-adjusted daily data since Mar 27, 1990, AXGN's average daily return is +0.32%, while the average monthly return is +2.91%. At this rate, your investment would double in approximately 2.0 years.

Historically, 47% of months were positive and 53% were negative. The best month was May 2007 with a return of +225.0%, while the worst month was Jul 2002 at -51.3%. The longest winning streak lasted 9 consecutive months, and the longest losing streak was 7 months.

On a daily basis, AXGN closed higher 38% of trading days. The best single day was Apr 30, 2003 with a return of +150.0%, while the worst single day was Feb 13, 2003 at -58.8%.


JanFebMarAprMayJunJulAugSepOctNovDecTotal
20266.48%-8.95%4.41%1.22%
202510.50%9.88%-7.55%-12.05%-33.07%-0.37%20.65%23.30%10.53%24.55%28.94%14.24%98.60%
202441.58%9.20%-23.58%-20.57%6.55%6.00%21.27%49.77%6.62%-0.14%-0.71%18.56%141.29%
2023-5.11%-12.88%14.55%-4.55%-5.76%7.41%-5.37%-27.55%-20.13%-24.80%74.20%4.27%-31.56%
2022-7.04%7.23%-14.99%-8.82%33.56%-15.31%13.80%0.54%27.21%-4.19%-4.12%-8.86%6.51%
2021-3.07%27.38%-8.33%-7.60%8.44%6.45%-5.74%-16.25%-7.39%-3.86%-37.00%-2.09%-47.65%

Benchmark Metrics

AxoGen, Inc. has an annualized alpha of 115.74%, beta of 0.48, and R² of 0.00 versus S&P 500 Index. Calculated based on daily prices since March 28, 1990.

  • This stock participated in 54.62% of S&P 500 Index downside but only 52.37% of its upside — more exposed to losses than it benefited from rallies.
  • Beta of 0.48 may look defensive, but with R² of 0.00 this stock is largely uncorrelated with S&P 500 Index — low beta reflects independence, not downside protection. See the Volatility section for a true picture of this stock's risk.
  • R² of 0.00 means this stock moves largely independently of S&P 500 Index — capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.

Alpha
115.74%
Beta
0.48
0.00
Upside Capture
52.37%
Downside Capture
54.62%

Return for Risk

Risk / Return Rank

AXGN ranks 76 for risk / return — better than 76% of stocks on our site. You're getting solid returns for the risk taken. A good sign, especially for investors who want growth without excessive volatility.


AXGN Risk / Return Rank: 7676
Overall Rank
AXGN Sharpe Ratio Rank: 8181
Sharpe Ratio Rank
AXGN Sortino Ratio Rank: 7777
Sortino Ratio Rank
AXGN Omega Ratio Rank: 7979
Omega Ratio Rank
AXGN Calmar Ratio Rank: 7272
Calmar Ratio Rank
AXGN Martin Ratio Rank: 7171
Martin Ratio Rank
The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

Return / Risk — by metrics

The table below present risk-adjusted performance metrics for AxoGen, Inc. (AXGN) and compare them to a chosen benchmark (S&P 500 Index).


AXGNBenchmarkDifference

Sharpe ratio

Return per unit of total volatility

1.34

0.90

+0.45

Sortino ratio

Return per unit of downside risk

1.97

1.39

+0.58

Omega ratio

Gain probability vs. loss probability

1.28

1.21

+0.06

Calmar ratio

Return relative to maximum drawdown

1.62

1.40

+0.22

Martin ratio

Return relative to average drawdown

3.82

6.61

-2.78

Explore AXGN risk-adjusted metrics in detail

Dive deeper into individual metrics with historical trends, benchmark comparisons, and performance across different time periods.

Dividends

Dividend History


AxoGen, Inc. doesn't pay dividends

Drawdowns

Drawdowns Chart

The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.


Loading graphics...

Worst Drawdowns

The table below displays the maximum drawdowns of the AxoGen, Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the AxoGen, Inc. was 98.49%, occurring on Aug 16, 2002. Recovery took 3701 trading sessions.

The current AxoGen, Inc. drawdown is 40.73%.


Depth

Start

To Bottom

Bottom

To Recover

End

Total

-98.49%Aug 28, 19912767Aug 16, 20023701May 1, 20176468
-93.54%Jul 24, 20181329Nov 1, 2023
-42.86%Apr 30, 1990183Jan 17, 199141Mar 18, 1991224
-21.42%Jan 8, 201823Feb 8, 201812Feb 27, 201835
-14.08%Aug 19, 19911Aug 19, 19916Aug 27, 19917

Volatility

Volatility Chart

The chart below shows the rolling one-month volatility.


Loading graphics...

Financials

Financial Performance

The chart below illustrates the trends in the financial health of AxoGen, Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.


Annual
Quarterly

0.0

Valuation

The Valuation section provides an overview of how AxoGen, Inc. is priced in the market compared to other companies in the Medical Devices industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.


PS Ratio

This chart shows the Price-to-Sales (P/S) ratio for AXGN relative to other companies in the Medical Devices industry. Currently, AXGN has a P/S ratio of 6.8. This P/S ratio is high relative to other companies in the industry. It could mean the stock is overvalued, or that investors expect strong future growth and profitability.

PB Ratio

The chart illustrates the Price-to-Book (P/B) ratio for AXGN in comparison with other companies in the Medical Devices industry. Currently, AXGN has a P/B value of 12.1. This P/B ratio is higher than most companies in the industry. It may suggest the stock is overvalued or that investors expect the company to generate high returns on its assets.

Income Statement



TTM
Revenue

Total Revenue

Cost Of Revenue

Gross Profit

Operating Expenses

Selling, General & Admin Expenses

R&D Expenses

Depreciation And Amortization

Total Operating Expenses

Income

Income Before Tax

Operating Income

EBITDA

EBIT

Earnings From Continuing Operations

Net Income

Income Tax Expense

Other Non-Operating Income (Expenses)

Extraordinary Items

Discontinued Operations

Effect Of Accounting Charges

Non Recurring

Minority Interest

Other Items

Interest Income

Interest Expense

Net Interest Income

Values in undefined except per share items